Evidence-based insights into peptide protocols, safety research, and optimization strategies. Built on clinical rigor, powered by community knowledge.
Get weekly insights on peptide protocols, safety updates, and optimization strategies delivered to your inbox.
No spam. Unsubscribe anytime. Clinical rigor, always.
Deep dives into peptide science — evidence-graded, honestly reported
We tested every peptide tracker app in 2026. Here's what we found, including where our competitors beat us.
The peptide tracker market went from empty to 15+ apps in 12 months. We tested them all and scored them on what matters: safety features, PK modelling, multi-compound support, and price. Pinned is ours. We're transparent about that.
Detailed compound profiles with mechanisms, safety data, and dosing protocols
RFK said peptides are back. The FDA hasn't published the rule change yet. Here's what's actually happening.
The FDA's 2026 peptide reclassification is a regulatory process, not a completed rule change. Seven compounds face PCAC review in July 2026, legal access requires a prescription, and the grey market remains unchanged until the FDA publishes.
You're spending $200–500/month on biological software and tracking it in a Notes app. The compounds aren't the problem. The total absence of protocol discipline is.
Peptide access exploded in 2026. Protocol discipline didn't follow. Most users are dosing from Reddit consensus, ignoring half-lives, missing timing windows, and running zero safety baselines. This article maps the specific failure modes, the insulin trap, the NO floor, the receptor ceiling, the sedentary trap, and what precision tracking actually looks like by comparison.
Fixed-ratio peptide blends promise synergy in a single vial — but pharmacokinetics, missing human data, and one-size-fits-all dosing tell a different story.
From BPC/TB duos to quad stacks, we examine why pre-mixed peptide blends fail the precision medicine test — mismatched half-lives, untested combinations, and the convenience tax you're actually paying.
A research-driven breakdown of what's actually inside the most popular peptide blend — and why fixed ratios create pharmacological problems your supplier won't mention.
Inside the KLOW quad stack: GHK-Cu, BPC-157, TB-500, and KPV. We examine the pharmacokinetic mismatches, the missing human trials, and why individual titration beats fixed-ratio convenience.
A four-amino-acid peptide that activates telomerase, remodels chromatin, and restores melatonin synthesis from the pineal gland — addressing five hallmarks of aging simultaneously. The Russian clinical data spans 12–15 years. Independent Western replication barely exists.
Epitalon (AEDG) is a synthetic tetrapeptide modeled after the bovine pineal extract Epithalamin. It upregulates hTERT to activate telomerase, remodels heterochromatin to re-access silenced genes, restores endogenous melatonin production (160% increase in clinical trials), and demonstrated a 28% decrease in overall mortality over a 12-year human follow-up. A 2025 study revealed selective ALT pathway activation in cancer cells. The compound remains investigational — nearly all positive data originates from a single institutional network in St. Petersburg, and independent Western replication is virtually absent.
35+
Articles
18
Categories